Scythian Biosciences Corp., of Toronto, reported results of preclinical studies of cannabinoid (CBD) and HU-211, a synthetic cannabinoid derivative, showing the combination improved cognitive functions of rodents with mild to moderate traumatic brain injury compared to vehicle, CBD alone and HU-211 alone.